What is the difference between Hypertrophic Obstructive Cardiomyopathy (HOCM) and Concentric Left Ventricular Hypertrophy (LVH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Hypertrophic obstructive cardiomyopathy (HOCM) and concentric left ventricular hypertrophy (LVH) are distinct cardiac conditions that require different management approaches, with HOCM being a genetic disorder characterized by asymmetric septal hypertrophy and dynamic left ventricular outflow tract obstruction, whereas concentric LVH represents a symmetric thickening of the left ventricular walls in response to pressure overload conditions. The key differences between HOCM and concentric LVH lie in their etiology, pathophysiology, and clinical presentation, as outlined in the 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy 1. HOCM is characterized by asymmetric septal hypertrophy, which can lead to dynamic left ventricular outflow tract obstruction and increased risk of sudden cardiac death. In contrast, concentric LVH is typically associated with symmetric thickening of the left ventricular walls, usually in response to pressure overload conditions such as hypertension or aortic stenosis, as described in the European Association of Cardiovascular Imaging (EACVI) and American Society of Echocardiography (ASE) recommendations on the use of echocardiography in adult hypertension 1.

Some of the key distinguishing features between HOCM and concentric LVH include:

  • Asymmetric septal hypertrophy in HOCM versus symmetric wall thickening in concentric LVH
  • Presence of outflow obstruction in HOCM, which is typically absent in concentric LVH
  • Different management approaches, with HOCM often requiring beta-blockers, calcium channel blockers, disopyramide, or surgical/interventional procedures, whereas concentric LVH management focuses on treating the underlying cause, such as blood pressure control
  • Importance of genetic testing in HOCM for family screening, whereas it is not typically indicated in concentric LVH

Echocardiography remains the primary diagnostic tool for differentiating between HOCM and concentric LVH, with cardiac MRI providing additional tissue characterization when needed, as recommended by the 2020 AHA/ACC guideline 1. The management of HOCM and concentric LVH should be guided by the underlying pathophysiology and clinical presentation, with a focus on relieving outflow obstruction and preventing sudden cardiac death in HOCM, and controlling blood pressure and reducing left ventricular wall thickness in concentric LVH.

From the Research

HOCM vs Concentric LVH: Key Differences

  • HOCM (Hypertrophic Obstructive Cardiomyopathy) is characterized by a left ventricular outflow tract (LVOT) gradient at rest or during provocation, as with Valsalva maneuver or exercise 2.
  • Concentric LVH (Left Ventricular Hypertrophy) is a condition where the left ventricle wall thickness increases in response to high blood pressure, without a significant LVOT gradient 3.

Management of HOCM

  • Management of HOCM encompasses activity restriction, prevention of sudden cardiac death, control of symptoms, and screening of relatives 2.
  • Pharmacologic treatment of symptoms in patients with HOCM consists of negative inotropic drugs, such as beta blockers, disopyramide, and nondihydropyridine calcium channel blockers 2, 4.
  • Septal reduction therapy (SRT) may be considered for patients with intolerable symptoms despite optimal conservative therapy 2, 5.

Comparison with Concentric LVH

  • Concentric LVH is often associated with hypertension, and blood pressure control with lifestyle changes and antihypertensive agents can prevent and regress LVH 3.
  • In contrast, HOCM is a primary cardiac disorder that requires specific management strategies, including septal reduction therapy and implantable cardioverter-defibrillators (ICDs) for high-risk patients 2, 4.

Treatment Outcomes

  • Disopyramide therapy has been shown to improve functional capacity in patients with obstructive HOCM, with 62% of patients achieving a 1-stage NYHA improvement compared to 26% in the control group 6.
  • However, there is limited direct comparison between HOCM and concentric LVH treatment outcomes, highlighting the need for further research in this area.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.

Current treatment options in cardiovascular medicine, 2012

Research

Left ventricular hypertrophy and hypertension.

Progress in cardiovascular diseases, 2020

Research

Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature.

Medical science monitor : international medical journal of experimental and clinical research, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.